Opening Hook When Delhi hospitals run out of beds faster than Coldplay tickets, diagnostic chains become the real rockstars. Enter Chandan Healthcare — a Lucknow-based multi-vertical player that has quietly scaled to ₹232.17 crore in FY25 revenues. EBITDA margins surged to 18.7% (from 6.9% in FY23), proving pathology reports can be more profitable than pathology classes. Listed only in Feb’25, the company already flaunts 40 diagnostic centres, 360 collection centres, and a pharmacy play, spreading across 44+ cities. But can a Tier-2/Tier-3 strategy really beat the big chains in Delhi-Mumbai? Stay tuned — this is healthcare with small-town swagger and investor-sized ambition.
At a Glance • Revenue ₹232.17 Cr – growth rate healthier than their patients • EBITDA ₹43.38 Cr – margins upgraded like Netflix from SD to 4K • PAT ₹22.17 Cr – 558% jump in two years, no steroids involved • ROE 27% – doctors would kill for this recovery speed • Debt-to-equity 0.39x – low enough to not raise BP
Management’s Key Commentary “We serve 18+ lakh patients annually.” Translation: Uttar Pradesh alone keeps us busy enough. “Our B2C, B2B, and B2G models ensure diversification.” Translation: Whoever pays, we test. “Expansion into Delhi, Bhopal, and Raipur is underway.” Translation: From Lucknow chai stalls to Connaught Place lattes. “We are focused on Tier-2 and Tier-3 markets.” Translation: Why fight Dr. Lal in Delhi when Bareilly is wide open? “Digital adoption via Chandan 24×7 app is strong.” Translation: We want to be your Swiggy of CT scans. “Our EBITDA margins improved significantly.” Translation: We finally figured out cost control, unlike government hospitals. “Promoter-led experience drives execution.” Translation: Trust the Gupta–Singh duo, we’ve done this for 20 years.
Numbers Decoded
Metric
Value
Takeaway
Revenue – The Hero
₹232.17 Cr
Grew 69% in two years, proving patients never stop coming.
EBITDA – The Sidekick
₹43.38 Cr
Margins jumped to 18.7%, finally acting like a private hospital.
PAT – The Drama Queen
₹22.17 Cr
From ₹3.36 Cr in FY23, this is a blockbuster sequel.
Analyst Questions Q: How sustainable are these margins? A: “Operating leverage from scale.” Translation: Bigger labs, smaller headaches. Q: What’s the expansion plan? A: “20+ new centres annually.” Translation: Aggressive franchising without calling it franchising. Q:
